How Much Does NovoLog Cost in 2026?

NovoLog and Fiasp (insulin aspart) are rapid-acting insulins. Medicare negotiated $119 for a 30-day supply, 76% below the $495 list price, effective January 1, 2026. For once, though, the negotiated price is not the number that decides your cost. A separate rule caps insulin cost-sharing on Medicare, and on NovoLog it works out to about $30 a month, not $35 and certainly not $119.

  • Medicare Part D caps your cost for a month's insulin at the lesser of $35, 25% of the negotiated price, or 25% of your plan's price. For NovoLog, 25% of $119 is about $29.75, so that is your ceiling.
  • There is no deductible on insulin under Part D. You pay the capped amount from the first fill of the year.
  • The negotiated price of $119 therefore saves you roughly $5 a month against the $35 cap. The rest of the saving accrues to Medicare, not to you.
  • NovoLog and Fiasp are the only insulins in the first negotiation round. If you take a different insulin, the flat $35 cap still applies to it.

What You Actually Pay

Figures are for a 30-day supply. List and negotiated prices are from CMS; what you pay depends on your coverage.

Your situationTypical cost
Medicare negotiated price, 2026$119 / 30 days
Medicare Part D, your share~$29.75 / month
Commercial insurancecopay or coinsurance
Uninsured, cash~$495 (list)

How the Insulin Cap and the Negotiated Price Interact

Two separate parts of the same law apply to NovoLog, and they stack in a way almost nobody explains. The first is the insulin provision: on Medicare Part D, a month's supply of a covered insulin cannot cost you more than $35, and no deductible applies. The second is negotiation, which set NovoLog's price at $119.

From 2026 the cap is defined as the lesser of $35, 25% of the maximum fair price, or 25% of the plan's negotiated price. Twenty-five percent of $119 is $29.75, which is less than $35, so that becomes your ceiling. The honest summary: if you are on Medicare and take NovoLog, your cost went from $35 to about $30. That is a real but modest improvement, and it is a far smaller change than the 76% headline suggests, because the insulin cap had already done most of the work.

Where the negotiated price does matter is if you are not on Medicare. The $35 cap and the negotiated price both apply only to Medicare. If you are uninsured or on a commercial high-deductible plan, neither protects you, and the manufacturer's own cash programs are the route to check.

What Medicare's Negotiated Price Does, and Does Not, Change

The headline number is not your copay.

$119 is the maximum fair price, the amount Medicare and your Part D plan pay for a 30-day supply of NovoLog. What you are charged at the counter is still set by your plan's tier and cost-sharing rules.

It helps you directly if you pay coinsurance

Many plans charge a percentage of the drug's price on brand and specialty tiers. If you owe 25% of $495, that is far more than 25% of $119. When your share is a percentage, a lower negotiated price lowers your bill directly.

It may not change a flat copay

If your plan charges a fixed dollar copay for that tier, your copay can stay the same even though the plan is paying less. The benefit then shows up in the program's overall costs rather than your receipt.

It changes how fast you hit the cap

Your spending counts toward the $2,100 annual Part D out-of-pocket cap in 2026. A cheaper drug means a smaller share each month, which can mean you reach the cap later or not at all, so the year-end picture differs from past years.

It does not change coverage rules

A negotiated price does not force a plan to cover NovoLog, drop prior authorization, or change its tier. Plans still set their own formularies, so check yours before you assume the new price applies to you.

Because tiers and cost-sharing vary so much between plans, the only way to know your real cost is to check NovoLog against each plan's formulary. If you would rather have that done for you, our Find My Medicare Plan service checks your specific drugs against the plans available to you for a flat $99.

Is There a Generic for NovoLog?

Not a generic, but there are lower-cost equivalents. Novo Nordisk sells an unbranded insulin aspart at a lower list price than NovoLog, and interchangeable biosimilar insulins exist for other insulin types. If you are on Medicare the $35 insulin cap generally makes this moot. If you are paying cash it is the main thing to ask about.

Does Insurance Cover NovoLog?

Usually, with conditions

NovoLog and Fiasp are covered by Medicare Part D and most commercial plans. On Medicare the insulin provision means no deductible and a capped monthly cost, so formulary tier matters far less here than for other drugs. Plans do still choose which insulins they cover, so if yours drops NovoLog, that is appealable and there is usually a covered alternative that is also subject to the cap.

If you are denied or moved a tier

A denial is not the end, and a tier change at renewal is not either. Your prescriber can submit a letter of medical necessity or a formulary exception, and you have formal appeal rights. See how to appeal an insurance denial and what to do when a plan drops your drug.

How to Pay Less

If you are on Medicare, confirm the cap is being applied

You should pay no more than about $30 for a month of NovoLog and no deductible should be charged. If your pharmacy charges more, something is wrong with how the claim was processed. Ask the pharmacy to reprocess it and call your plan. This is one of the most common insulin billing errors.

If you are not on Medicare, go to the manufacturer programs

Neither the $35 cap nor the negotiated price reaches commercial or uninsured patients. Novo Nordisk offers cash programs and an unbranded insulin aspart at a lower list price, and its patient assistance program can be $0 if your income qualifies.

On Medicare, check Extra Help and the payment plan

Extra Help (the Low Income Subsidy) sharply reduces Part D costs and its income limits are higher than most people expect. The Medicare Prescription Payment Plan can also spread your Part D costs evenly across the year instead of front-loading them, and you opt in through your plan.

Check the tier before you commit to a plan

The same drug can cost very different amounts across plans in the same ZIP code. During open enrollment, compare NovoLog on each plan's formulary, and remember the plan that was cheapest last year may not be this year.

Push back on a bill you have already received

If you were billed more than you expected, or a claim was processed wrong, CareRoute Bill Defense reviews and disputes medical bills, with no fee unless we save you money.

Not sure which plan covers NovoLog best?

For a flat $99, we research the Medicare plans available to you and check them against your specific drugs and doctors, then hand you a clear comparison. We are independent, sell no insurance, and take no commissions.

Frequently Asked Questions

How much does NovoLog cost on Medicare in 2026?

About $30 for a 30-day supply, with no deductible. Medicare Part D caps your cost for a month's insulin at the lesser of $35, 25% of the negotiated maximum fair price, or 25% of your plan's negotiated price. Since NovoLog's negotiated price is $119, 25% of it is $29.75, and that becomes your ceiling. If your pharmacy charges you more than that, or applies a deductible, the claim was processed incorrectly and should be reprocessed.

Does the negotiated price actually save me money on insulin?

Only a little, and that is worth being clear about. Insulin on Medicare Part D was already capped at $35 a month with no deductible before negotiation took effect. The negotiated price of $119 lowers the cap to 25% of that, about $29.75, so the practical saving for a Medicare patient is roughly $5 a month. The larger share of the 76% reduction accrues to Medicare rather than to you. If you are uninsured or on commercial insurance, neither the cap nor the negotiated price applies to you at all.

What is Medicare's negotiated price for NovoLog?

Medicare negotiated a maximum fair price of $119 for a 30-day supply of NovoLog, effective January 1, 2026. That is 76% below the $495 list price CMS used as the comparison. NovoLog was one of the first ten drugs in the Medicare Drug Price Negotiation Program, selected because it was among the highest-spending Part D drugs without generic or biosimilar competition at the time. The price applies automatically at the pharmacy for Part D members.

Will the negotiated price lower what I actually pay for NovoLog?

It can, but it is not your new copay. The maximum fair price is what Medicare and your Part D plan pay the pharmacy, not automatically what you are charged. If your plan charges coinsurance, a percentage of the drug price, a lower negotiated price lowers your share directly. If your plan charges a flat copay for that tier, your copay may not change at all. Either way, your total Part D out-of-pocket is capped at $2,100 in 2026, after which covered drugs cost you nothing for the rest of the year.

Does insurance cover NovoLog?

Generally yes. NovoLog is covered by Medicare Part D and most commercial plans, though plans commonly require prior authorization and sometimes step therapy, meaning you try a cheaper option first. The tier it sits on, not whether it is covered, is usually what decides your cost, and the same drug can sit on different tiers in two plans sold in the same ZIP code. Check your plan's formulary for the tier and any restrictions before you fill it.

Related

Sources

  • CMS, Medicare Drug Price Negotiation Program: Negotiated Prices for Initial Price Applicability Year 2026 (maximum fair price and list-price comparison)
  • CMS / Medicare.gov (Part D out-of-pocket cap, $2,100 in 2026, and the $615 maximum deductible)
  • FDA Orange Book and Purple Book (approval and substitutability status for insulin aspart)
  • Novo Nordisk published list price and patient-support program terms

Prices are national figures for a 30-day supply at a common dose and vary by pharmacy, dose, and plan. List prices are the figures CMS published as its negotiation comparison. This page is educational and is not medical or financial advice: do not start, stop, or switch a prescription on the basis of price without talking to your prescriber. Last updated November 20, 2026.